Geneva, Switzerland, January 5, 2024 – 6pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the appointment of Anke Post, MD, PhD as Chief Medical Officer, effective immediately, as David Leppert, MD, retires.